<SEC-DOCUMENT>0001564590-18-007944.txt : 20180410
<SEC-HEADER>0001564590-18-007944.hdr.sgml : 20180410
<ACCEPTANCE-DATETIME>20180410165832
ACCESSION NUMBER:		0001564590-18-007944
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180409
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180410
DATE AS OF CHANGE:		20180410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iRhythm Technologies, Inc.
		CENTRAL INDEX KEY:			0001388658
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				208149544
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37918
		FILM NUMBER:		18748510

	BUSINESS ADDRESS:	
		STREET 1:		650 TOWNSEND STREET
		STREET 2:		SUITE 380
		CITY:			San Francisco
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		415-632-5700

	MAIL ADDRESS:	
		STREET 1:		650 TOWNSEND STREET
		STREET 2:		SUITE 380
		CITY:			San Francisco
		STATE:			CA
		ZIP:			94103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IRhythm Technologies, Inc.
		DATE OF NAME CHANGE:	20110429

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IRhythm Technologies Inc
		DATE OF NAME CHANGE:	20070201
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>irtc-8k_20180409.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irtc-8k_20180409.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;border-top:Solid 0.75pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:32.86%;margin-right:32.86%;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K<font style="font-size:12pt;font-weight:normal;">&#160;</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:32.86%;margin-right:32.86%;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of report (Date of earliest event reported): April&#160;9, 2018</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:32.86%;margin-right:32.86%;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:32.86%;margin-right:32.86%;text-indent:0%;font-size:7pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0001-37918</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20-8149544</p></td>
</tr>
<tr style="height:20.9pt;">
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification Number)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">650 Townsend Street, Suite 500</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California 94103</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive office) (Zip Code)</p>
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(415) 632-5700</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:32.86%;margin-right:32.86%;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:7pt;margin-bottom:0pt;text-indent:3.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:89.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:89.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:89.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:6.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:89.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-top:7pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</p>
<p style="margin-top:7pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:7pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="border-top:Solid 0.75pt;padding-top:1pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:2pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.02 </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(d) Election of Director; Appointment of Committee Members</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.37%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 9, 2018, the Board of Directors (the &#8220;Board&#8221;) of iRhythm Technologies, Inc. (the &#8220;Company&#8221;) approved an increase in the size of the Board by one director, from seven to eight directors, and appointed C. Noel Bairey Merz to the Board, effective immediately. Dr. Bairey Merz will serve as a Class II director, with a term expiring at the annual meeting of stockholders to be held in 2018<font style="color:#000000;">, when she is expected to stand for election by a vote of the Company&#8217;s stockholders.</font> In addition, the Board appointed Dr. Bairey Merz as a member of the Compensation Committee of the Board, effective immediately.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.37%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Bairey Merz has been the Medical Director of the Preventive and Rehabilitative Center at the Cedars-Sinai Medical Center in Los Angeles, California, since 1991. She also has been the Medical Director and Endowed Chair of the Barbra Streisand Women&#8217;s Heart Center at the Smidt Cedars-Sinai Heart Institute since 2001, and a Professor of Medicine at Cedars-Sinai Medical Center and the David Geffen School of Medicine at the University of California at Los Angeles. From 2005 to 2009, she served on the Scientific Advisory Board of CV Therapeutics, Inc. She also has extensive experience on nonprofit boards, councils, and guideline panels including the American College of Cardiology, the American Heart Association and the National Heart, Lung, and Blood Institute. Since 2016, Dr. Bairey Merz has been serving on multiple editorial boards including the Journal of the American College of Cardiology, Circulation, and European Heart Journal. Dr. Bairey Merz holds a B.A. (Honors) in Biological Sciences from the University of Chicago and an M.D. (Honors) from Harvard Medical School. She completed her training in Internal Medicine at the University of California, San Francisco, and Cardiology at Cedars-Sinai Medical Center.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.37%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the appointment of Dr. Bairey Merz on April 9, 2018, Dr. Bairey Merz was granted an award of restricted stock units covering 3,120 shares of the Company&#8217;s common stock. The restricted stock unit award will vest over a three-year period with one third of the restricted stock units scheduled to vest on each of the first three anniversaries of the grant date, subject to the continued service on the Board on each applicable vesting date. The restricted stock unit award is subject to the terms and conditions of the Company&#8217;s 2016 Equity Incentive Plan and its related grant agreement. As a director, Dr. Bairey Merz will participate in the compensation program applicable to all non-employee directors, which is described under the heading &#8220;Director Compensation&#8221; in the Company&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 27, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.37%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Bairey Merz also executed the Company&#8217;s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-213773) filed with the Securities and Exchange Commission on September 23, 2016.</p>
<p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:5.37%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no arrangements or understandings between Dr. Bairey Merz and any other persons pursuant to which Dr. Bairey Merz was elected as a director.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.37%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 10, 2018, the Company issued a press release announcing appointment of Dr. Bairey Merz. The press release is attached hereto as Exhibit 99.1.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:17.78%;"></td>
<td style="width:84.59%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements and Exhibits.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.77%;text-indent:-15.77%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:17.78%;"></td>
<td style="width:84.59%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="irtc-ex991_57.htm"><font style="text-decoration:underline;">Press Release issued by iRhythm Technologies, Inc. dated April 10, 2018.</font></a></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;margin-right:4.38%;text-indent:7.89%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.37%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:104.1%;">
<tr>
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRHYTHM TECHNOLOGIES, INC.</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.85pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:/s/ Kevin M. King</p></td>
</tr>
<tr style="height:23.85pt;">
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.85pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin M. King</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;April 10, 2018</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>irtc-ex991_57.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irtc-ex991_57.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201804101831363378320.jpg" title="" alt="" style="width:192px;height:70px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies Appoints UCLA and Cedars-Sinai Professor C. Noel Bairey Merz, M.D. to its Board of Directors </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">SAN FRANCISCO &#8211; April 10, 2018 &#8211;<font style="font-weight:normal;"> iRhythm Technologies, Inc.&#160;(NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the appointment of C. Noel Bairey Merz, M.D. to its Board of Directors. Dr. Bairey Merz is the Medical Director of the Preventive and Rehabilitative Center at the Cedars-Sinai Medical Center in Los Angeles, California, where she also serves as the Medical Director and Endowed Chair of the Barbra Streisand Women&#8217;s Heart Center at the Smidt Cedars-Sinai Heart Institute. Additionally, she is a Professor of Medicine at Cedars-Sinai Medical Center and the David Geffen School of Medicine at the University of California at Los Angeles. Dr. Bairey Merz will serve on iRhythm&#8217;s compensation committee.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are pleased to welcome Dr. Bairey Merz to our Board and look forward to the contributions she will make,&#8221; said Kevin King, President and CEO of iRhythm Technologies. &#8220;Given her remarkable and extensive clinical experience in cardiology and her involvement with a wide range of organizations, we are confident she will provide unique and valuable insights that will help iRhythm navigate the ever-evolving healthcare landscape. Her background and skills will complement the depth of business insights and knowledge of our current board members.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An international figure in preventive cardiology and heart disease in women, Dr. Bairey Merz previously served on nonprofit boards including the American College of Cardiology and the American Heart Association. Since 2016, Dr. Bairey Merz has served on multiple editorial boards including the Journal of the American College of Cardiology, Circulation and European Heart Journal. She is also chair of the National Institutes of Health (NIH)-sponsored WISE (Women's Ischemic Syndrome Evaluation) initiative. From 2005 to 2009, she served on the Scientific Advisory Board of CV Therapeutics, Inc. Dr. Bairey Merz holds a B.A. (Honors) in Biological Sciences from the University of Chicago and an M.D. (Honors) from Harvard Medical School. She completed her training in Internal Medicine at the University of California, San Francisco, and Cardiology at Cedars-Sinai Medical Center.&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"I am honored to join iRhythm&#8217;s Board of Directors," said Dr. Bairey Merz. &#8220;Throughout my career I&#8217;ve embraced innovation, and iRhythm is bringing exciting new technology to cardiology that clearly benefits both providers and patients. I look forward to leveraging my expertise and contributing to the company&#8217;s clinical strategy to further iRhythm&#8217;s leadership in cardiac monitoring.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;border-top:Solid 0.75pt #0093B2;padding-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies, Inc<font style="font-weight:normal;">.&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;650 Townsend Street, Suite 500&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;San Francisco, CA&nbsp;&nbsp;94103</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">phone: 415.632.5700&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;fax: 415.632.5701&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:none;color:#31849B;">irhythmtech.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201804101831363378320.jpg" title="" alt="" style="width:192px;height:70px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;color:#auto;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About </font><font style="font-weight:bold;color:#auto;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies, Inc. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company <font style="font-size:12pt;">combines</font> wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lynn Pieper Lewis or Leigh Salvo</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415) 937-5404</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investors@irhythmtech.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cherise Adkins</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415) 486-3235</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">media@irhythmtech.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;border-top:Solid 0.75pt #0093B2;padding-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies, Inc<font style="font-weight:normal;">.&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;650 Townsend Street, Suite 500&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;San Francisco, CA&nbsp;&nbsp;94103</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">phone: 415.632.5700&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;fax: 415.632.5701&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:none;color:#31849B;">irhythmtech.com</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g201804101831363378320.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201804101831363378320.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[@ .061O8F4 9      !_^$.?D5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    )    '(!,@ "    %    ):':0 $
M 0   *H   #* )8    !    E@    $  $%D;V)E(%!H;W1O<VAO<"!#0R R
M,#$U("A-86-I;G1O<V@I #(P,3<Z,#$Z,3 @,30Z,3(Z,38   *@ @ $
M 0   2R@ P $     0   &X         !@$#  ,    !  8   $:  4    !
M   !& $;  4    !   !( $H  ,    !  (   (!  0    !   !* ("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M[M#=NUW]9^4QW_6UM?XJ^G?8?J;BO+2VS-?9E6 _RCZ51'];'II<M7K?U/\
MJ[U^^O(ZOBG)MI9Z=9]6U@#9W?0HMJ9](K4Q,6C#Q:<3&;Z>/CUMJI9).UC
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M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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MJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?K_Q  ? 0
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M]B]6[^W=@Z*FI16SU68V[M7*Y;&0I2&.5:C76TB J48$7N"./9SR[80[IO\
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MZ?8(TK_INA)_>#\T^#L7M]R7%)FXNIKR0>@@00PU^3&XFI\T^SH /Y 75_\
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M+.SK$@<K&I8LSTU$T%22>N FX\\^Y?NGOUEM&\\W[E?7.XWB11PR7$S0AYY
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MN!XBI6&,2(3)\)J:$Z6H(/\ I V;_H__ -*?\?H_]'W]SO\ 2!_>C34?P_\
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M>&\=OSPIM//9WJ+?NX-RX2I-0):=-NY3(=55>4QLYJWU(*:1&\AN/5[>^GN
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MQLM)IXS.WS\9BZ'_ )QE!^77"K[UG-/]:_??GN>.35:V4ZV48XZ?I$6*4?\
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MI!G(-.C3N?(8R',;J?1]5\NY,C5/8\^KGGWSYYTW;]^<V<P[J&U1S7<A0_\
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MR-]X;=OI.4MOVI&I)>78)'K'"I9OV.8NL?ON$\K?O7W2WWF>6.MOM.UL%/\
M#/=.(T_;"ER/]1ZVX_>&?77?I*;\W?C.OMC[RW[FVT8;9&U-Q;OR[ZPFG&;:
MQ%9F:]M; JFFEHG-SP/:S;K*7<MPL=N@'Z]Q,D:_Z9V"C^9Z*=^WBUY>V/>M
M_OC2RL;2:XD\NR&-I'S_ *53U\[6JGW+VIV%45+ALGO#L?>4L[*NK5D-R[PS
M;2$+?6^JKRF1X^I]7Y]]+T6UVC;50=EE:P ?Z5(U_P BKU\Z,LFY\U\PR2D>
M+O.Y7I/^GFN):_\ &G?^?7T*]K87;G2'3^W=O>=*3:7476^)PYJM 1*?;VPM
MLP4;5)2X"B/'8HN1?\?7WS8O)[K?]ZNKG3JO+VZ9J>KS2$T_WIJ=?0_M5EMO
M(W)VW;=X@3:-GVV./5P AM8 NK\DCKU\][?>ZLWVSV=O'>M7!-5;C[*WWN#=
M%131WGGJ,SO#/U>5DIXK"\LLE;D2B_U)'OI+M]I!LVU6-@C 6UK;I&#P 6-
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MP/7RV_\ H'%_G7?]X&;_ /\ T8'2/_VS_9K]3!_OS_#U2A].OJ@?RTOC1/\
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H]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
